Weiss Ratings Reaffirms "Sell (D-)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Key Points

• Weiss Ratings has reaffirmed a sell (D-) rating for 4D Molecular Therapeutics (NASDAQ: FDMT) amid mixed analyst opinions.
• The stock is currently trading at $4.36 with a market capitalization of approximately $202 million and an average target price of $29.56.
• Recent earnings report indicated a loss of ($0.86) EPS, missing estimates and highlighting negative trends in return on equity and net margin.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

A number of other equities research analysts have also recently commented on FDMT. The Goldman Sachs Group cut their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Chardan Capital reissued a "buy" rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, July 3rd. Finally, Barclays cut their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Price Performance

FDMT stock traded up $1.92 during midday trading on Tuesday, hitting $6.42. The stock had a trading volume of 31,473,829 shares, compared to its average volume of 360,319. The firm has a market cap of $297.44 million, a price-to-earnings ratio of -2.02 and a beta of 2.83. The business has a 50-day moving average of $4.21 and a two-hundred day moving average of $4.05. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. Research analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently modified their holdings of FDMT. BVF Inc. IL boosted its position in shares of 4D Molecular Therapeutics by 70.8% during the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after buying an additional 1,890,647 shares during the last quarter. Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after acquiring an additional 1,337,497 shares during the period. Federated Hermes Inc. lifted its holdings in 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock valued at $4,038,000 after acquiring an additional 1,246,419 shares during the period. JPMorgan Chase & Co. lifted its holdings in 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after acquiring an additional 504,086 shares during the period. Finally, Norges Bank bought a new position in 4D Molecular Therapeutics in the fourth quarter valued at about $2,790,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.